Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16100517 | 0.95 | CHIA (0.60) | CHIAOPRK1HRH3MAPTLMNA | |
| SCHEMBL7241637 | 0.89 | OPRK1 (0.55) | CHIAOPRK1HRH3MAPTLMNA | |
| SCHEMBL38658667 | 0.88 | L3MBTL1 (0.62) | OPRK1HRH3MAPTLMNAL3MBTL1 | |
| SCHEMBL30397636 | 0.88 | L3MBTL1 (0.62) | OPRK1HRH3MAPTLMNAL3MBTL1 | |
| SCHEMBL7242883 | 0.85 | MAPT (0.59) | CHIAOPRK1HRH3MAPTLMNA | |
| SCHEMBL14488641 | 0.85 | MAPT (0.72) | CHIAOPRK1HRH3MAPTLMNA | |
| SCHEMBL6965268 | 0.84 | OPRK1 (0.56) | OPRK1HRH3MAPTLMNAL3MBTL1 | |
| SCHEMBL16105029 | 0.84 | OPRK1 (0.61) | OPRK1HRH3MAPTLMNA | |
| SCHEMBL394318 | 0.84 | OPRK1 (0.54) | CHIAOPRK1HRH3MAPTLMNA | |
| SCHEMBL593819 | 0.84 | KMT2A (0.69) | CHIAMAPTLMNAL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-2968299-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10266551-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2968299-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014150258-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-6562827-B1 | For the treatment of diseases in which increased calpain activity occurs such as neurodegenerative diseases or neuronal damage are caused by ischemia, trauma or mass hemorrhages | ABBOTT LABORATORIES | 2003-05-13 | — | — | US | disclosed |
| EP-0385350-B1 | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-4994456-A | Hypotensive agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0385350-A1 | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHIA 2826/4885OPRK1 3114/4885HRH3 3914/4885 |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHIA 2826/4885OPRK1 3114/4885HRH3 3914/4885 |
| US-10266551-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CHIA 2826/4885OPRK1 3114/4885HRH3 3914/4885 |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHIA 2826/4885OPRK1 3114/4885HRH3 3914/4885 |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CHIA 2826/4885OPRK1 3114/4885HRH3 3914/4885 |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHIA 2826/4885OPRK1 3114/4885HRH3 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.